ArticleCancer reports (Hoboken, N.J.)2026
Antiproliferative Effect of 24-Deoxysericoside From Terminalia macroptera Guill. & Perr. (Combretaceae) Against Breast Carcinoma: In Vitro, Molecular Docking and ADME Assessment.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTerminalia macroptera (Combretaceae) is an important medicinal plant in the traditional pharmacopeia in most tropical areas, where its different parts are used in treating illnesses including cancer.
aimsIn this study, two oleanane-type triterpenoids: terminolic acid (TM32) and arjungenin (TM34), together with three saponins: arjunglucoside I (TM35), 24-deoxysericoside (TM36) and chebuloside II (TM37) from T. macroptera, were screened for their cytotoxic effects against breast cancer cell lines. METHODS AND
resultsThe compounds were isolated using column chromatography and characterized from their NMR data. Their cytotoxic and antiproliferative effects against estrogen non-sensitive (MDA-MB 231) and estrogen sensitive (MCF-7) breast cancer cell lines were evaluated. Against estrogen non-sensitive (MDA-MB 231) cancer cell lines, deoxysericoside (TM36) was profoundly active compared to the control. Terminolic acid (TM32), arjungenin (TM34), and arjunglucoside I (TM35) were also active. Against estrogen sensitive (MCF-7) breast cancer cell lines, deoxysericoside (TM36) exhibited significant activity (p < 0.05) compared to control experiments. The most active compound had an optimum concentration of 30 μg/mL. Deoxysericoside (TM36) showed concentration-dependent inhibition percentages at 15 and 30 μg/mL, and MDA-MB 231 breast carcinoma cells were more susceptible. MDA-MB 231 treated with 15 and 30 μg/mL of deoxysericoside (TM36) showed significant reduction (p < 0.05) in clone formation after 48 h when compared to untreated controls, suggesting that it can restrict cancer to a preliminary stage. The deoxysericoside (TM36) reduced cell migration with dose-dependent improvement in wound healing at 15 and 30 μg/mL, revealed by the micrographs. Molecular docking indicated that the compounds fit well into hERα and PI3Kα receptor binding sites, forming stable complexes with binding energies in ranges of -9.04 to -5.02 kcal mol
conclusionThe studies showed that the isolated compounds could be used for the development of anticancer therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.